241 related articles for article (PubMed ID: 18285836)
21. The BRCT domain is a phospho-protein binding domain.
Yu X; Chini CC; He M; Mer G; Chen J
Science; 2003 Oct; 302(5645):639-42. PubMed ID: 14576433
[TBL] [Abstract][Full Text] [Related]
22. Phosphopeptide interactions with BRCA1 BRCT domains: More than just a motif.
Wu Q; Jubb H; Blundell TL
Prog Biophys Mol Biol; 2015 Mar; 117(2-3):143-148. PubMed ID: 25701377
[TBL] [Abstract][Full Text] [Related]
23. The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity.
Sum EY; Peng B; Yu X; Chen J; Byrne J; Lindeman GJ; Visvader JE
J Biol Chem; 2002 Mar; 277(10):7849-56. PubMed ID: 11751867
[TBL] [Abstract][Full Text] [Related]
24. Toward classification of BRCA1 missense variants using a biophysical approach.
Rowling PJ; Cook R; Itzhaki LS
J Biol Chem; 2010 Jun; 285(26):20080-7. PubMed ID: 20378548
[TBL] [Abstract][Full Text] [Related]
25. Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del.
De Nicolo A; Parisini E; Zhong Q; Dalla Palma M; Stoeckert KA; Domchek SM; Nathanson KL; Caligo MA; Vidal M; Cusick ME; Garber JE
Cancer Res; 2009 Sep; 69(17):7030-7. PubMed ID: 19706752
[TBL] [Abstract][Full Text] [Related]
26. Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat.
Cortesi L; De Nicolo A; Medici V; Marino M; Turchetti D; Pradella LM; Rossi G; Parisini E; Federico M
Breast Cancer Res Treat; 2012 Jul; 134(1):435-41. PubMed ID: 22527099
[TBL] [Abstract][Full Text] [Related]
27. The BRCA1 C-terminal domain: structure and function.
Huyton T; Bates PA; Zhang X; Sternberg MJ; Freemont PS
Mutat Res; 2000 Aug; 460(3-4):319-32. PubMed ID: 10946236
[TBL] [Abstract][Full Text] [Related]
28. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
[TBL] [Abstract][Full Text] [Related]
29. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
30. Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.
Lovelock PK; Healey S; Au W; Sum EY; Tesoriero A; Wong EM; Hinson S; Brinkworth R; Bekessy A; Diez O; Izatt L; Solomon E; Jenkins M; Renard H; Hopper J; Waring P; Tavtigian SV; Goldgar D; Lindeman GJ; Visvader JE; Couch FJ; Henderson BR; Southey M; Chenevix-Trench G; Spurdle AB; Brown MA;
J Med Genet; 2006 Jan; 43(1):74-83. PubMed ID: 15923272
[TBL] [Abstract][Full Text] [Related]
31. Substantial evidence for the clinical significance of missense variant BRCA1 c.5309G>T p.(Gly1770Val).
Tudini E; Moghadasi S; Parsons MT; van der Kolk L; van den Ouweland AMW; Niederacher D; Feliubadaló L; Wappenschmidt B; Spurdle AB; Lazaro C
Breast Cancer Res Treat; 2018 Nov; 172(2):497-503. PubMed ID: 30105462
[TBL] [Abstract][Full Text] [Related]
32. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation.
Williams RS; Glover JN
J Biol Chem; 2003 Jan; 278(4):2630-5. PubMed ID: 12427738
[TBL] [Abstract][Full Text] [Related]
33. Effect of BRCA1 missense variants on gene reversion in DNA double-strand break repair mutants and cell cycle-arrested cells of Saccharomyces cerevisiae.
Lodovichi S; Bellè F; Cervelli T; Lorenzoni A; Maresca L; Cozzani C; Caligo MA; Galli A
Mutagenesis; 2020 Mar; 35(2):189-195. PubMed ID: 31769492
[TBL] [Abstract][Full Text] [Related]
34. DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains.
Yu X; Chen J
Mol Cell Biol; 2004 Nov; 24(21):9478-86. PubMed ID: 15485915
[TBL] [Abstract][Full Text] [Related]
35. Phosphopeptide interactions of the Nbs1 N-terminal FHA-BRCT1/2 domains.
Kim K; Kirby TW; Perera L; London RE
Sci Rep; 2021 Apr; 11(1):9046. PubMed ID: 33907233
[TBL] [Abstract][Full Text] [Related]
36. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
[TBL] [Abstract][Full Text] [Related]
37. Inter-BRCT linker is probably the most intolerant region of the BRCA1 BRCT domain.
Yadegari F; Farahmand L; Esmaeili R; Zarinfam S; Majidzadeh-A K
J Biomol Struct Dyn; 2024 Jul; 42(11):5734-5746. PubMed ID: 37948190
[TBL] [Abstract][Full Text] [Related]
38. Thermal denaturation of the BRCT tandem repeat region of human tumour suppressor gene product BRCA1.
Pyrpassopoulos S; Ladopoulou A; Vlassi M; Papanikolau Y; Vorgias CE; Yannoukakos D; Nounesis G
Biophys Chem; 2005 Apr; 114(1):1-12. PubMed ID: 15792855
[TBL] [Abstract][Full Text] [Related]
39. HP1 regulates the localization of FANCJ at sites of DNA double-strand breaks.
Wu W; Togashi Y; Johmura Y; Miyoshi Y; Nobuoka S; Nakanishi M; Ohta T
Cancer Sci; 2016 Oct; 107(10):1406-1415. PubMed ID: 27399284
[TBL] [Abstract][Full Text] [Related]
40. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.
De Nicolo A; Tancredi M; Lombardi G; Flemma CC; Barbuti S; Di Cristofano C; Sobhian B; Bevilacqua G; Drapkin R; Caligo MA
Clin Cancer Res; 2008 Jul; 14(14):4672-80. PubMed ID: 18628483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
